Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Shares and Warrants (Tables)

Common Shares and Warrants (Tables)

3 Months Ended

Nov. 30, 2019

Equity [Abstract]

Schedule of option and warrant exercises

Type of Issuance		Number of Shares				Total Value
Private placement			1,823,745				820,685
			1,823,745			$	820,685

Schedule of warrant

		Number of Warrants				Weighted Average Exercise Price $
Balance, August 31, 2018			3,286,274				0.72
Cancelled/Expired			(17,498	)			0.59
Exercised			(1,626,513	)			0.49
Issued			1,183,062				1.99
Balance, August 31, 2019			2,825,325				1.38
Issued			2,057,495				0.80
Balance November 30, 2019			4,882,820				1.14

Schedule of warrants granted as compensation warrants by using the Black-Scholes option pricing model

		November 30 2019
Expected volatility			91%
Risk-free interest rate			2.87%
Expected life			2 years
Dividend yield			0.00%
Estimated fair value per warrant			$0.28 - $0.43

Schedule of warrants outstanding

# of Warrants			Weighted Average Remaining Contractual Life		Weighted Average Exercise Price $
250,000			0.01 years			0.83
500,000			0.13 years			1.83
975,325			0.92 years			2.25
100,000			1.48 years			0.96
250,000			1.48 years			1.55
750,000			1.86 years			0.14
225,000			2.00 years			0.80
1,832,495			2.00 years			0.80
4,882,820			1.46 years			1.14